CompletedPhase 2

Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder

Taiwan61 participantsStarted 2016-04

Plain-language summary

Alzheimer's disease (AD) and Parkinson's disease (PD) are currently the leading neurodegenerative disorders. Considering the fact that aged population is rapidly growing, it has become a critical issue to find more effective medications for these two disorders. The aim of this project is to examine the effectiveness and safety of DAAOI-P treatment for PD with dementia.

Who can participate

Age range50 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Diagnosis of PD according to Queen Square Brain Bank criteria
✓. A dementia syndrome with insidious onset and slow progression, developing within the context of established PD and diagnosed by history, clinical, and mental examination, defined as:
✓. Cognitive features: Impaired attention, executive functions, visuo-spatial functions or memory. Core functions of language are largely preserved.
✓. Behavioral features:
✓. Acute confusion due to systemic illnesses or drug intoxication.
✓. Major depression

Exclusion criteria

✕. Patients with uncontrollable malignancy, severe heart failure, uremia under hemodialysis, or decompensated liver cirrhosis.
✕. Patients taking anticholinergics within 30 days of recruitment.

What they're measuring

The improvement of gait and neuropsychiatric symptoms

Timeframe: week 0, 8, 16, 24

Trial details

NCT IDNCT04470037

SponsorChina Medical University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12

View on ClinicalTrials.gov More Parkinson's Disease With Dementia trials